Linked Life Data

3218975

Source:http://linkedlifedata.com/resource/pubmed/id/3218975

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
1989-3-6
pubmed:abstractText
L1210 leukemia was used to evaluate the antitumour activity in vivo of CY233 (NSC 609224) a new water-soluble nitrosoureido derivative of deoxysugar currently being studied in preclinical trials. The antitumour activity of CY233 is dose-dependent with the same large therapeutic index whatever the route of administration (I.P., I.V., per os). Thus starting from a single dose of 10 mg/kg (less than 25% of the LD50), 80% to 100% of mice survive at 120 days, whether the drug is being administered I.V., I.P. or P.O. These results clearly emphasize the very original and promising potentiality of CY233 among the series of alkylating agents, and more precisely nitrosoureas.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0250-7005
pubmed:author
pubmed:issnType
Print
pubmed:volume
8
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1419-22
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:articleTitle
Antitumour activity of a new water-soluble nitrosoureido sugar: CY233 (NSC 609224).
pubmed:affiliation
Pavillon de Recherche, Institut Gustave-Roussy, Villejuif, France.
pubmed:publicationType
Journal Article, Comparative Study